BBLG Stock Overview
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.
Bone Biologics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.05|
|52 Week High||US$7.12|
|52 Week Low||US$1.02|
|1 Month Change||-21.64%|
|3 Month Change||-17.97%|
|1 Year Change||n/a|
|3 Year Change||-95.06%|
|5 Year Change||-99.20%|
|Change since IPO||-98.98%|
Recent News & Updates
We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|BBLG||US Biotechs||US Market|
Return vs Industry: Insufficient data to determine how BBLG performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BBLG performed against the US Market.
|BBLG Average Weekly Movement||13.9%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.6%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: BBLG is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: BBLG's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company’s NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1.
Bone Biologics Fundamentals Summary
|BBLG fundamental statistics|
Is BBLG overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BBLG income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.18|
|Net Profit Margin||0.00%|
How did BBLG perform over the long term?See historical performance and comparison
Is BBLG undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 0/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BBLG?
Other financial metrics that can be useful for relative valuation.
|What is BBLG's n/a Ratio?|
Price to Book Ratio vs Peers
How does BBLG's PB Ratio compare to its peers?
|BBLG PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
ALLR Allarity Therapeutics
PTIX Protagenic Therapeutics
DFFN Diffusion Pharmaceuticals
BBLG Bone Biologics
Price-To-Book vs Peers: BBLG is expensive based on its Price-To-Book Ratio (1.9x) compared to the peer average (0.8x).
Price to Earnings Ratio vs Industry
How does BBLG's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: BBLG is expensive based on its Price-To-Book Ratio (1.9x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is BBLG's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||1.9x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate BBLG's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of BBLG when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate BBLG's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate BBLG's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Bone Biologics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if BBLG's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if BBLG's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if BBLG's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if BBLG's revenue is forecast to grow faster than the US market.
High Growth Revenue: BBLG is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BBLG's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Bone Biologics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BBLG is currently unprofitable.
Growing Profit Margin: BBLG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BBLG is unprofitable, but has reduced losses over the past 5 years at a rate of 45.6% per year.
Accelerating Growth: Unable to compare BBLG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BBLG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).
Return on Equity
High ROE: BBLG has a negative Return on Equity (-33.03%), as it is currently unprofitable.
Discover strong past performing companies
How is Bone Biologics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BBLG's short term assets ($5.7M) exceed its short term liabilities ($70.6K).
Long Term Liabilities: BBLG's short term assets ($5.7M) exceed its long term liabilities ($10.0).
Debt to Equity History and Analysis
Debt Level: BBLG is debt free.
Reducing Debt: BBLG currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BBLG has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: BBLG has sufficient cash runway for 2.5 years if free cash flow continues to grow at historical rates of 29.7% each year.
Discover healthy companies
What is Bone Biologics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|Bone Biologics Dividend Yield vs Market|
|Company (Bone Biologics)||n/a|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||4.7%|
|Industry Average (Biotechs)||2.8%|
|Analyst forecast in 3 Years (Bone Biologics)||n/a|
Notable Dividend: Unable to evaluate BBLG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BBLG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BBLG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BBLG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as BBLG has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jeff Frelick (56 yo)
Mr. Jeffrey Frelick, also known as Jeff, has been the President and Chief Executive Officer at Bone Biologics Corporation since June 28, 2019. He served as Chief Operating Officer at Bone Biologics, Corp....
CEO Compensation Analysis
|Jeff Frelick's Compensation vs Bone Biologics Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jun 30 2022||n/a||n/a|
|Mar 31 2022||n/a||n/a|
|Dec 31 2021||US$290k||US$245k|
|Sep 30 2021||n/a||n/a|
|Jun 30 2021||n/a||n/a|
|Mar 31 2021||n/a||n/a|
|Dec 31 2020||US$300k||US$240k|
|Sep 30 2020||n/a||n/a|
|Jun 30 2020||n/a||n/a|
|Mar 31 2020||n/a||n/a|
|Dec 31 2019||US$300k||US$240k|
|Sep 30 2019||n/a||n/a|
|Jun 30 2019||n/a||n/a|
|Mar 31 2019||n/a||n/a|
|Dec 31 2018||US$300k||US$240k|
|Sep 30 2018||n/a||n/a|
|Jun 30 2018||n/a||n/a|
|Mar 31 2018||n/a||n/a|
|Dec 31 2017||US$300k||US$240k|
|Sep 30 2017||n/a||n/a|
|Jun 30 2017||n/a||n/a|
|Mar 31 2017||n/a||n/a|
|Dec 31 2016||US$771k||US$288k|
|Sep 30 2016||n/a||n/a|
|Jun 30 2016||n/a||n/a|
|Mar 31 2016||n/a||n/a|
|Dec 31 2015||US$2m||US$113k|
Compensation vs Market: Jeff's total compensation ($USD290.00K) is below average for companies of similar size in the US market ($USD772.00K).
Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.
Experienced Management: BBLG's management team is seasoned and experienced (7.8 years average tenure).
Experienced Board: BBLG's board of directors are considered experienced (9.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Bone Biologics Corporation's employee growth, exchange listings and data sources
- Name: Bone Biologics Corporation
- Ticker: BBLG
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$10.868m
- Shares outstanding: 10.35m
- Website: https://www.bonebiologics.com
Number of Employees
- Bone Biologics Corporation
- 2 Burlington Woods Drive
- Suite 100
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BBLG||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Dec 2015|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/30 00:00|
|End of Day Share Price||2022/09/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.